Here’s why the Imugene (ASX:IMU) share price is rising 9% today

The Imugene Limited (ASX: IMU) share price is on the rise today. This comes after the company received a successful outcome from the Cohort Review Committee (CRC) regarding its PD1-Vaxx immunotherapy.

PD1-Vaxx is a B-cell immunotherapy designed to treat tumours by producing polyclonal antibodies that block PD-1 signalling, causing an anti-cancer effect.

During mid-afternoon trade, the Imugene shares are up 9.5% to 12 cents.

First checkpoint passed

The Imugene share price is rising deeper into positive territory following the release.

According to Imugene, the CRC cleared the pathway for phase I clinical trials to be proceed with a higher dose of PD1-Vaxx.

Following patient data review, CRC unanimously decided that the immunotherapy…